The FDA has flagged these risks with BPC-157
Neuroprotection & Longevity
The peptide reduces production of pro-inflammatory cytokines including IL-1, TNF-, and IL-6 while enhancing expression of anti-inflammatory mediators such as IL-10 and TGF-, creating a cytokine milieu that supports tissue repair rather than ongoing damage
The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States
Many of the people surveyed would prefer their injections to be overseen by a doctor but felt they had no choice but to self-medicate more frequently to improve their quality of life
Learn when to use this code, documentation requirements, reimbursement considerations, and how OptiMantra streamlines lab ordering, result tracking, and billing workflows